The Pharma Data

NOVEMBER 15, 2020

” Arthur Oubrie, Chief Scientific Officer of Lead Pharma, added: “This is the second project we partner with one of the largest pharmaceutical companies under our Discover, Design and Deliver platform. . OSS, Netherlands , Nov. About Lead Pharma. For more information visit: www.leadpharma.com.

Small Molecule 52

Small Molecule Licensing Licensing Disease 52

Drug Target Review

APRIL 5, 2024

For example, a CDMO with deep sequencing knowledge and a proprietary cell line will achieve significantly better performance than CDMOs that license third-party technologies. Skilled CDMOs can also locate or create favourable genomic microenvironments where transcription factors are efficiently recruited, further boosting protein production.

Protein Production 96

Protein Production Protein Expression Bioinformatics Production 96

The Pharma Data

MARCH 2, 2021

Boehringer Ingelheim and Gubra today announced a new research and licensing agreement focused on the identification and validation of targets and innovative peptide compounds for the treatment of obesity.

Treatment 52

Treatment Bioinformatics Clinical Development Therapies 52

DrugBank

MARCH 15, 2023

The moment you decide which DrugBank license or products best suit your needs isn’t the final step in our relationship, it is just the beginning. Depending on your unique needs, license*, and project goals, you might interact with all of them firsthand, or you might be off and running with just a little help from one team.

Licensing 52

Licensing Licensing International Bioinformatics 52

The Pharma Data

DECEMBER 27, 2020

United Therapeutics is developing Tyvaso DPI under a collaboration and license agreement with MannKind Corporation. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership.

FDA 52

FDA Bioinformatics Disease Production 52

The Pharma Data

OCTOBER 27, 2020

License-related fees (5). License-related fees (5). The BREEZE study (NCT03950739) seeks to evaluate 45 patients on a stable dose of Tyvaso after switching to our new dry powder inhaler (DPI) form of treprostinil, which we licensed from MannKind Corporation. .

FDA 40

FDA Production Licensing Licensing 40

Drug Target Review

FEBRUARY 11, 2025

The major hurdles that pharmaceutical companies face are long lead times, high costs and a low probability of success (PoS). Improving drug development success in the face of increasingly complex therapies is therefore a priority for the pharmaceutical industry. Clinical bioinformatics desiderata for Molecular Tumor Boards.

Drug Development 59

Drug Development Bioinformatics Drugs Small Molecule 59